LeonaBio, Inc. Common Stock (LONA) Stock Price

LONAStock
$5.20+42.08%52W
Market Cap$48.99M
P/E—
PEG Ratio—
Div yield—
Beta1.96

LONA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-52.57%
Price vs S&P 500 (4W)-16.53%
VGM Score48.41

LONA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$1.36-$0.80+41.03%(+$0.56)
Q1 2026-$2.50-$1.73+30.80%(+$0.77)
Q4 2025-$1.27-$18.92-1393.68%(-$17.65)
Q3 2025-$1.22-$1.68-37.70%(-$0.46)
Q2 2025-$1.40-$1.80-28.57%(-$0.40)

LONA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.11
4.11
4.10
4.10

Industry Peers — Biological Products(186)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
LONALeonaBio, Inc. Common Stock
——C————$5.20
AMGNAmgen IncDCA6.1x9.1%74.3%2.9%$432.49
GILDGilead Sciences IncCBA6.4x5.5%79.6%133.6%$156.19
MRNAModerna, Inc. Common StockFCA39.1x-27.6%36.4%—$218.01
ARGXargenx SE American Depositary SharesDAB6.6x165.2%89.8%—$819.14
RVMDRevolution Medicines, Inc. Common StockF—B3296.2x———$177.96
BIIBBiogen Inc. Common StockCDA3.4x0.3%74.0%-18.8%$232.65
BNTXBioNTech SE American Depositary ShareCCC7.6x-11.8%79.2%—$87.71
EXELExelixis IncCBA6.3x9.2%96.5%31.1%$62.23
HALOHalozyme Therapeutics, Inc.DBA8.3x41.1%82.4%22.9%$121.84
NBIXNeurocrine Biosciences IncCBB4.1x34.4%98.0%2.3%$135.71

About LeonaBio, Inc. Common Stock

LeonaBio Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for serious diseases with significant unmet medical needs. The company focuses on treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), two conditions with limited existing treatment options. LeonaBio's pipeline targets patient populations facing critical therapeutic gaps and represents potential first-in-class or best-in-class opportunities.